| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | gene | 한글 | 유전자 |
|---|---|---|---|
| 설명 | 유전자는 길게 띠를 형성한 DNA분자의 일부분으로 한 가지 물질을 만드는데 필요한 모든 정보를 갖춘 기능적인 단위이다. 예를 들어 인슐린이라는 물질의 유전자라고 하면 사람의 세포내에 있는 긴 DNA 분자 중에서 인슐린이라는 물질을 만드는데 필요한 모든 정보를 가지고 있는 한 부분을 가리키는 말이다. 고전적인 생물학에서는 유전자가 표현형을 결정하거나 지정하는 염색체의 일부분이라고 정의되었지만, 오늘날에는 유전자에 대해서 분자적 정의가 제안되고 있으며 그 정의는 하나의 유전자는 하나의 효소를 결정 또는 암호화하는 유전물질의 일부분이라는 개념으로 이것이 이른바 1개의 유전자 1개 효소가설(one gene-one enzyme hypothesis)이다. 즉 1개의 유전자는 1개의 효소를 제작하는데 필요한 유전정보를 가진다는 것이다. 현재 이 가설이 받아들여지고 있다. |
||
| 영문 | gene therapy | 한글 | 유전자요법 |
|---|---|---|---|
| 설명 | 유전병을 치료할 목적으로, 정상적으로 기능하는 단일유전자 혹은 복수유전자를 어떤 기원에서 얻어내어 생세포에 도입하는 것. 유전물질은 유전자삽입 조작에 의해 수용세포에로 도입된다. 즉, 유전자를 끼워 넣은 새로운 세포를 사용하는 치료로서 1980년 미국의 학자가 지중해빈혈환자에게 강행하여 비판을 받았지만, 미국 국립보건연구소는 1990년 9월 아데노신 데아미나아제(adenosine deaminase, ADA) 결핍증 환자의 림프구에 ADA 유전자를 끼워 넣는 치료를 시작한 이래 현재는 암을 포함한 많은 질병들을 치료하는 목적으로 쓰인다. |
||
| 영문 | muscle cell(=muscle fiber) | 한글 | 근육세포 |
|---|---|---|---|
| 설명 | 근육은 수의근(의식에 의해서 조절이 가능한 근육: 예를 들어 다리, 팔, 얼굴근육 등)과 불수의근(의식과 무관하게 조절하지 않아도 움직이는 근육: 예를 들어 심장근, 소화기관에 분포하는 근육 등)으로 나누어지며, 근육세포의 모양은 다음과 같다(수의근, 불수의근 외에 심장에 있는 심장근은 불수의근에 해당하지만 그 모양은 수의근과 같아 따로 분류한다).  |
||
| 영문 | white blood cell(WBC), leukocyte | 한글 | 백혈구 |
|---|---|---|---|
| 설명 | 혈액내에 골수구계세포와 림프계세포, 단핵구계세포를 모두 통틀어 말한다. 백혈구의 증가가 있으면 대개 감염이 있거나, 혹은 탈수현상이 있음을 의미한다. 또한 지나친 백혈구수의 감소는 인체내 면역기능이 떨어져 있음을 의미하며, 다른 질병에 의해 나타나는 이차적인 현상이 아닌지 꼭 진단을 받아보아야 한다. |
||
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
|---|---|
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
| MCC | mean corpuscular hemoglobin concentration; medial cell column; Medical Council of Canada; metacerebr... |
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| VDR | Vitamin D receptor gene |
|---|---|
| AR | androgen receptor gene |
| HU-MARA | human androgen receptor gene |
| LDLR | low density lipoprotein receptor gene |
| RYR1 | ryanodine receptor gene |
| gene rearrangement, alpha-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors. (12 Dec 1998) |
|---|---|
| gene rearrangement, beta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, delta-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the delta-chain of antigen receptors. (12 Dec 1998) |
| gene rearrangement, gamma-chain T-cell antigen receptor | Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors. (12 Dec 1998) |
| genes, T-cell receptor | DNA sequences, in cells of the t-lymphocyte lineage, that code for T-cell receptors. The tcr genes are formed by somatic rearrangement (see gene rearrangement, t-lymphocyte and its children) of germline gene segments, and resemble ig genes in their mechanisms of diversity generation and expression. (12 Dec 1998) |
| genes, T-cell receptor alpha | DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes. (12 Dec 1998) |
| genes, T-cell receptor beta | DNA sequences encoding the beta chain of the T-cell receptor. The genomic organization of the tcr beta genes is essentially the same in all species and is similar to the organization of ig genes. (12 Dec 1998) |
| genes, T-cell receptor delta | DNA sequences encoding the delta chain of the T-cell receptor. The delta-chain locus is located entirely within the alpha-chain locus. (12 Dec 1998) |
| genes, T-cell receptor gamma | DNA sequences encoding the gamma chain of the T-cell receptor. The human gamma-chain locus is organised similarly to the tcr beta-chain locus. (12 Dec 1998) |
| receptor-CD3 complex, antigen, T-cell | Molecule composed of the non-covalent association of the T-cell antigen receptor (receptors, antigen, T-cell) with the CD3 complex (antigens, CD3). This association is required for the surface expression and function of both components. The molecule consists of up to seven chains: either the alpha/beta or gamma/delta chains of the T-cell receptor, and four or five chains in the CD3 complex. (12 Dec 1998) |
| T-cell receptor | <immunology> The antigen recognising receptor on the surface of T-cells. Heterodimeric (disulphide linked), one of the immunoglobulin superfamily of proteins, binds antigen in association with the major histocompatibility complex (MHC), leading to the activation of the cell. There are two subunits (_ and _, 42-44 kD in mouse, 50-40 kD in humans), each with variable and constant regions, that are associated noncovalently with T3 (20-30 kD). A second heterodimer on CD3 cells with _ (35 kD in mice, 55 kD in humans) and _ (45 kD in mice, 40 kD in humans) chains is a second T-cell antigen receptor that is not MHC restricted. The __ T-cell receptors (TCRs) are formed on very early T-cells in the thymus. (18 Nov 1997) |
| cell division cycle gene | Genes which control the yeast cell cycle. There are around 50 different genes which do this. (09 Oct 1997) |
| somatic cell gene therapy | The repair or replacement of a defective gene within somatic tissue. (09 Oct 1997) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|